Aquestive Therapeutics (AQST) Tax Provisions (2023 - 2024)
Aquestive Therapeutics' (AQST) quarterly Tax Provisions came in at -$14000.0 in Q4 2024, down 113.86% year-on-year from $101000.0 in Q1 2024, and down 113.86% quarter-over-quarter from $101000.0 in Q4 2023.
Aquestive Therapeutics (AQST) Tax Provisions (2023 - 2024) Analysis & Trends
Aquestive Therapeutics' Tax Provisions history runs 2 years deep, the most recent figure standing at -$14000.0 for Q4 2024.
- On a quarterly basis, Tax Provisions fell 113.86% year-over-year to -$14000.0 in Q4 2024; TTM through Mar 2025 was -$14000.0, a 105.71% decrease from a year earlier, with the FY2024 full-year figure at -$14000.0, down 105.71% from the prior year.
- Tax Provisions eased to -$14000.0 in Q4 2024 per AQST's latest filing, from $101000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $284000.0 in Q2 2023 and bottomed at -$140000.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 67.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 157.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 676.90 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -423.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 48.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 30.00 Mn |
| 10 | Aquestive Therapeutics | 462.24 Mn | 462.24 Mn | 13.47 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -14,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Sep 30, 2023 | -140,000.00 |
| Jun 30, 2023 | 284,000.00 |